BNP Paribas Financial Markets
KNSA icon

BNP Paribas Financial Markets’s Kiniksa Pharmaceuticals KNSA Stock Holding History

BNP Paribas Financial Markets’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.2M Sell
647,731
-184,046
-22% -$8.15M 0.02% 907
2025
Q4 		$34.3M Buy
831,777
+178,366
+27% +$7.16M 0.02% 877
2025
Q3 		$25.4M Buy
653,411
+227,464
+53% +$7.39M 0.01% 983
2025
Q2 		$11.8M Buy
425,947
+200,517
+89% +$5.1M 0.01% 1323
2025
Q1 		$5.01M Buy
225,430
+51,950
+30% +$1.07M ﹤0.01% 1812
2024
Q4 		$3.43M Sell
173,480
-19,446
-10% -$444K ﹤0.01% 2032
2024
Q3 		$4.82M Buy
192,926
+105,924
+122% +$2.58M ﹤0.01% 1524
2024
Q2 		$1.62M Buy
87,002
+40,942
+89% +$767K ﹤0.01% 2025
2024
Q1 		$909K Sell
46,060
-30,608
-40% -$598K ﹤0.01% 2555
2023
Q4 		$1.34M Buy
76,668
+7,846
+11% +$129K ﹤0.01% 2203
2023
Q3 		$1.2M Sell
68,822
-10,053
-13% -$169K ﹤0.01% 2217
2023
Q2 		$1.11M Sell
78,875
-47,671
-38% -$638K ﹤0.01% 2132
2023
Q1 		$1.36M Buy
126,546
+91,547
+262% +$1.21M ﹤0.01% 2111
2022
Q4 		$524K Buy
34,999
+24,207
+224% +$352K ﹤0.01% 2545
2022
Q3 		$139K Sell
10,792
-6,148
-36% -$70K ﹤0.01% 3643
2022
Q2 		$164K Sell
16,940
-44,257
-72% -$413K ﹤0.01% 3171
2022
Q1 		$608K Buy
61,197
+4,289
+8% +$45.4K ﹤0.01% 2643
2021
Q4 		$670K Buy
56,908
+51,275
+910% +$630K ﹤0.01% 2854
2021
Q3 		$64.2K Buy
5,633
+4,559
+424% +$59.4K ﹤0.01% 3444
2021
Q2 		$15K Sell
1,074
-2,425
-69% -$36.8K ﹤0.01% 3621
2021
Q1 		$64.8K Buy
3,499
+414
+13% +$8.47K ﹤0.01% 3524
2020
Q4 		$54.5K Sell
3,085
-3,305
-52% -$58.1K ﹤0.01% 3513
2020
Q3 		$97.9K Buy
6,390
+5,003
+361% +$93.9K ﹤0.01% 3128
2020
Q2 		$35.3K Sell
1,387
-3,139
-69% -$65.6K ﹤0.01% 3175
2020
Q1 		$70.1K Buy
4,526
+2,284
+102% +$35.7K ﹤0.01% 3386
2019
Q4 		$24.8K Buy
2,242
+26
+1% +$226 ﹤0.01% 3939
2019
Q3 		$18.9K Buy
2,216
+679
+44% +$7.5K ﹤0.01% 3973
2019
Q2 		$20.8K Sell
1,537
-1,148
-43% -$17.8K ﹤0.01% 3881
2019
Q1 		$48.5K Buy
2,685
+2,467
+1,132% +$47.7K ﹤0.01% 3507
2018
Q4 		$6.12K Buy
218
+80
+58% +$1.67K ﹤0.01% 3512
2018
Q3 		$3.52K Buy
+138
New +$2.68K ﹤0.01% 4167

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BNP Paribas Financial Markets's KNSA Position: Q1 2026 in Review

BNP Paribas Financial Markets reduced its Kiniksa Pharmaceuticals (KNSA) stake by 22% in Q1 2026, selling an estimated $8.15M and leaving 647,731 shares worth $31.2M. The position accounts for 0.02% of the portfolio, ranked #907.

BNP Paribas Financial Markets first reported a position in KNSA in Q3 2018 and has held it in 31 quarters since. The position peaked at $34.3M in Q4 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • BNP Paribas Financial Markets held 647,731 shares of Kiniksa Pharmaceuticals worth $31.2M as of Q1 2026.
  • BNP Paribas Financial Markets sold 184,046 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $8.15M.
  • Kiniksa Pharmaceuticals made up 0.02% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #907 holding.
  • BNP Paribas Financial Markets first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • BNP Paribas Financial Markets's Kiniksa Pharmaceuticals position peaked at $34.3M in Q4 2025.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.